First-time moms in the US are getting older as new average age is revealed
A report from the agency revealed an uptick of nearly a year, rising from 26.6 in 2016 to 27.5 in 2023.
'All racial and ethnic groups saw an increase in mean age at first birth of 0.4 to 1.4 years,' the National Vital Statistics System authors wrote. The system provides the most complete data on births and deaths in the U.S.
The results indicate a continual trend over the past several decades, they noted, with the average age jumping or remaining stable every year since 1970. The spike reflects changes in social, political, education, and economic factors. More women are working now than ever before and there have been fewer teenaged pregnancies. It's also more expensive than ever to have children. In fact, many people are choosing not to have kids because of that cost and fears over climate change.
While the report did not get into regional break downs, it looked at changes by urbanicity. In 2016 to 2023, the same 0.9-year increase was found across large central, large fringe, and medium metropolitan areas. For small metropolitan and nonmetropolitan areas, the change was just 0.7 years.
'Mothers living in large fringe or large central metropolitan areas had the highest mean age at first birth (27.6 in 2016 and 28.5 in 2023),' they found. Whereas, those in noncore areas had the lowest average age at first birth, until 25 years old.
The report also analyzed the breakdown by race, finding that Asian American mothers had the largest increase in average age, at 1.4 years. They also had the highest average age at first birth in 2016 and 2023, at 30.1 and 31.5 years, respectively.
Conversely, American Indian and Alaska Native mothers had the lowest mean age at first birth in 2016 and 2023, at 23.2 and 24.2 years old.
'The increase in the mean age of mothers from 2016 to 2023 is the result of declines in first births to mothers younger than 25 and increases in first births to mothers age 30 and older,' the authors noted.
'The ongoing rise in the age of mothers at first birth reflects changes in childbearing for U.S. families,' the report said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
I'm 37 but get mistaken for being 19 after using 69p frozen item every day & it gets rid of dark eye circles too
WHEN it comes to maintaining a youthful complexion, many typically think of pricey Botox treatments. But according to one thrifty beauty buff, the answer can be found in your fridge - and it's a fan favourite in salads. 2 Amal K., from San Francisco, may be almost 40 - but at 37 she looks so radiant and wrinkle-free that many mistaken her for a teenager. The dark-haired beauty regularly shares her top tips for skincare, such as eating sardines - however, Amal recently stunned with an easy hack that costs less than £1. As well as eating a nutrient-dense diet, the TikToker likes to ensure her skincare routine is top tip - and there's one key step that might surprise you. To kickstart her morning skincare, Amal likes to use a frozen cucumber slashed in half that's been sitting in the freezer overnight. In the now-viral-video, the savvy beauty buff explained she used it as ''a natural Gua Sha''. This traditional Chinese medicine technique involves scraping the skin with a smooth-edged tool to relieve hypertension and improve circulation. The method has become a hit on social media ever since it took off - and even Kendal Jenner swears by this ancient technique. Meanwhile, using a frozen cucumber on your face can offer temporary de-puffing and soothing effects due to its cold temperature - ideal for that morning puffiness. ''I am 37 years old, and I have never had Botox or fillers. One thing I do daily is an ice facial - but today, we are going to use a frozen cucumber'' she said in another clip. ''Before you start, make sure your face is nice and clean. ''Cucumber contains vitamin K, so it is just going to help curb the appearance of dark circles, help the lymphatic around your eyes and reduce the appearance of puffiness. ''We all love that, right? It also helps blood circulation, brightens your skin, minimises pores.'' After you are done, she said, don't throw the whole cucumber - simply cut the top little piece off and throw the remaining cucumber back in the freezer for use again. ''It's good up to 3 weeks,'' she said in the comments. Why is turmeric good for anti-ageing? A study published in the Asia Pacific Journal of Clinical Nutrition suggests that turmeric and curcumin may help prevent DNA damage and aid in DNA repair. This is promising news for disease prevention and slowing the ageing process. It also: Boosts Collagen Production: Collagen is a protein that maintains the skin's elasticity and firmness. As we age, collagen production decreases, leading to wrinkles and sagging skin. Turmeric helps stimulate collagen synthesis, thereby promoting firmer and more youthful skin. Improves Skin Health: Turmeric has been shown to improve various skin conditions, such as acne, psoriasis, and eczema. Its antibacterial and anti-inflammatory properties help soothe the skin, reduce redness, and promote a clearer complexion. Next, let the cucumber water sit on your face for a few minutes, before splashing your face with cold water - and continue with the rest of the routine. If you've run out of cucumber, you can snap up this salad - and skincare - staple for a mere 69p from Aldi and other supermarkets. The clip, posted under the username @ amalkzad has taken the internet by storm, winning the stunner a whopping 2.1million views. As 152k users gave it a like, close to 800 people flooded to comments, where many refused to believe her age. ''She don't look 30, she don't look so, she looks 19,'' wrote one person. A fellow beauty buff was clearly so impressed by the results they were keen to give the hack a go themselves. ''Girl you look 19,'' someone else wrote.
Medical News Today
2 hours ago
- Medical News Today
Experimental drug eliminates aggressive breast, skin cancer in small trial
Scientists have developed a new cancer drug that can be injected directly into tumors. The treatment, an enhanced CD40 agonist, was successful in its first trial of 12 human participants. Six people in the group saw their tumors shrink, while two participants saw their cancer go completely into remission. The National Institutes of Health project that doctors will diagnose at least 2 million new cancer cases and that 600,000 people will die from cancer in 2025 in the United improving cancer death rates, this prediction highlights the need to continue developing more effective treatments. Researchers from Rockefeller University made headway in this area with the completion of their human phase 1 study. They tested a new CD40 antibody drug, 2141-V11, designed to shrink tumors and reduce side new drug had promising results, shrinking tumors in half the patients and completely eliminating cancer in two cases, while not causing serious side effects. The study appears in the journal Cancer Cell.A new approach to cancer immunotherapyMany cancer treatments exist, and sometimes treatment can be as simple as removing the tumor or lesion for localized cancers. In cases where the cancer is metastatic and has spread, more aggressive treatments are necessary. Some types of more aggressive cancer treatments include: radiation therapychemotherapyhormone American Cancer Society describes immunotherapy as a 'treatment that uses the body's immune system, usually your own, to attack cancer.' There are several types of immunotherapy, such as immune checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Researchers in the new study focused on immunotherapy — specifically, the CD40 agonist antibody drug class, a type of monoclonal antibody treatment. It works by activating the CD40 receptor and causing an immune system response. According to the study authors, research on CD40 has not been successful in human trials in the past and has caused serious side effects. This led the scientists to create an engineered form of CD40 called 2141-V11. The drug was designed to improve the issues with CD40 and reduce systemic inflammation and liver toxicity. The scientists also decided to inject the treatment directly into the tumor instead of administering it intravenously. For the human study, the researchers recruited 12 participants, and everyone in the group had metastatic cancers including melanoma and breast cancer. The participants ranged from ages 42 to participants received injections of 2141-V11 into their tumors every 3 weeks, with an increased dosage each results with limited toxicityThroughout the 2141-V11 treatments, the researchers monitored the side effects and bloodwork of the participants. They were especially concerned with the participants' platelet count and liver enzymes since these would indicate a treatment-related adverse event (TRAE). By the end of the treatment, ten participants experienced adverse events, and seven experienced TRAEs. However, none of the patients experienced any TRAEs higher than grade 3, and the researchers considered the drug 'well tolerated.' Most of the side effects were mild and included fever and issues where the drug was injected. Three participants had severe adverse events, but the researchers did not consider them TRAEs. One participant had to be hospitalized because of a urinary tract infection, and another had shortness of breath related to chronic heart failure. No serious dose-limiting toxicities occurred, and the participants' liver and platelet levels were stable throughout treatment. Additionally, cancer tumors shrank in six of the participants, and two participants went into complete remission. One of the participants who went into remission had melanoma, and the other had breast cancer. The researchers noted that not only did their tumors shrink, but tumors in the rest of the body disappeared. Wael Harb, MD, a board-certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers, spoke with Medical News Today and explained how the cancer drug works.'This drug (2141-V11) is an engineered antibody that flips a key 'ON' switch (CD40) on immune cells inside a tumor,' said Harb, who was not involved in the recent trial. 'It's injected directly into one tumor, where it organizes immune cells into mini lymph nodes called tertiary lymphoid structures (TLS).' 'Those act like on-site training camps that activate cancer-killing T-cells, which then travel through the body to attack tumors that weren't injected,' Harb he noted that the drug's safety profile was encouraging, he emphasized that larger trials are needed. 'Twelve patients are too few to draw firm safety conclusions across cancers–larger trials are needed and are already underway,' the oncologist is next for 2141-V11?Study author Juan Osorio, MD, director Of Clinical Operations And Translational Immunology at Rockefeller University, spoke with MNT and discussed the future of the research with 2141-V11. 'We look forward to the results of several ongoing phase 2 studies nationwide, targeting difficult-to-treat cancers, such as malignant gliomas, bladder cancer, and prostate cancer,' said Osorio. Osorio mentioned that early data from the phase 2 studies is 'promising,' but it is not a one-size-fits-all solution for people with cancer. 'Not all patients respond, highlighting the need for rational combination strategies to extend the benefit of this therapy,' Osorio shared. Osorio said the team is currently trying to figure out which biomarkers may predict response to CD40 agonists. 'Furthermore, we want to evaluate in larger cohorts whether TLS or other immune spatial interactions are crucial for effective induction of antitumor immunity. Answering these questions will be critical to fully translate this approach into meaningful and durable clinical benefit for patients.'
Daily Mail
3 hours ago
- Daily Mail
Mass poisoning. Mind control. And weather tampering. The TRUTH about 'chemtrails'
The white lines seen following airplanes as they fly could be full of harmful chemicals that are toxic in Americans' health, some people claim. The streaks left across the sky from planes, called contrails, are formed by water vapor from the plane's exhaust freezing in the cold air at high altitudes. Your browser does not support iframes.
